OncClub: Join the Chat on Trending Trials in Cancer Final results from the Phase 3 ClarIDHy trial Lively expert panel discussions featuring peer-to-peer exchanges Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

OncClub: Join the Chat on Trending Trials in Cancer Final results from the Phase 3 ClarIDHy trial Lively expert panel discussions featuring peer-to-peer exchanges Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

View More Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma

Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma

All Oncology News

Pipeline Report

Rare Cancer Series

OncClub All Oncology News Pipeline Report Rare Cancer Series

Medical World News

Thoracic Night Live

Insights Medical World News News Network OncLive TV Peer Exchange Podcasts Rapid Readouts The Talk Thoracic Night Live

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

Giants of Cancer Care PER Events Scientific Interchanges State of the Science Summit / IPC Webinars

Oncology Fellows

Supplements And Featured Publications

All Publications

Oncology Live Oncology Fellows Supplements And Featured Publications All Publications

Interactive Tools

Learning Modules

Community Interactive Tools Learning Modules Partners Sponsored

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2021 MJH Life Sciences and OncLive. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Final results from the Phase 3 ClarIDHy trial
Lively expert panel discussions featuring peer-to-peer exchanges
Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

OncLive SOSS

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2021 MJH Life Sciences^™ and OncLive. All rights reserved.

The Future of RET Inhibitors in Non-Small Cell Lung and Thyroid Cancer

EP. 1: Why RET Alteration is an Attractive Target for Therapy

October 18th 2019

EP. 2: RET Fusion, Point Mutation, and Signaling

October 18th 2019

EP. 3: Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

October 18th 2019

EP. 4: RET Treatment: Novel Compounds to Replace Current TKIs

October 18th 2019

EP. 5: The Importance of NGS Testing

October 18th 2019

EP. 6: RET Testing in Papillary and Medullary Thyroid Cancer

October 18th 2019

EP. 7: LIBRETTO-001 Regimen Overview

October 18th 2019

EP. 8: LOXO-292 in Patients With RET-Fusion Lung Cancer

October 18th 2019

EP. 9: ESMO 2019 LIBRETTO-001 Trial Updates

October 18th 2019

EP. 10: How BLU-667 Has Changed the Treatment Landscape

October 18th 2019

<
1
2
>